Taxotere for Anthracycline Refractory Advanced Breast Cancer
COLLEGEVILLE, Penn--Rhône-Poulenc Rorer Inc.'s Taxotere (docetaxel) is now available for treatment of patients with locally advanced or metastatic breast cancer that has progressed during anthracycline-based therapy or relapsed during anthracycline-based adjuvant therapy.
COLLEGEVILLE, Penn--Rhône-Poulenc Rorer Inc.'s Taxotere(docetaxel) is now available for treatment of patients with locallyadvanced or metastatic breast cancer that has progressed duringanthracycline-based therapy or relapsed during anthracycline-basedadjuvant therapy.
In clinical studies, Taxotere has shown the highest response rateever (47%) for a single agent in this patient population at adose of 100 mg/m² given IV over 1 hour every 3 weeks, "avery convenient administration schedule," Howard A. BurrisIII, MD, of the Cancer Therapy and Research Center, San Antonio,said at a teleconference held to launch the new product.
Dr. Burris noted that "with a drug with this much impactin shrinking tumors in the advanced stage, the hope is that wewill eventually be able to bring it into stage I, II, and IIItreatment, and those clinical trials are ongoing."
The pivotal Taxotere trials were reported in this publicationin Nov 1995, page 1, and June 1996, page 16.
The Proper Ways to Identify and Use ADCs in Breast Cancer Subtypes
June 29th 2025Deciding when to use immunotherapy and how to utilize antibody-drug conjugates are complicated processes that require multidisciplinary collaboration to ensure that all patients with breast cancer receive appropriate and efficient care.
